Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Bücher
Zeitschriften
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
ATZ-Fachkongress

Chassis.tech plus 2024


4 Kongresse in einer Veranstaltung

Treffen Sie in München die Fachleute von Chassis, Lenkung, Bremsen sowie Reifen/Räder.
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Cancer and Tumor Development: Biomedical Background Kapitel lesen Erstes Kapitel lesen

2015 | OriginalPaper | Buchkapitel

5. Optimal Control of Mathematical Models for Antiangiogenic Treatments

verfasst von : Heinz Schättler, Urszula Ledzewicz

Erschienen in: Optimal Control for Mathematical Models of Cancer Therapies

Verlag: Springer New York

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

In the models considered so far, the focus was on the cancerous cells progressing from mathematical models for homogeneous tumor populations of chemotherapeutically sensitive cells to heterogeneous structures of cell populations with varying sensitivities or even resistance. From an optimal control point of view, optimal treatment schedules change from bang-bang solutions with upfront dosing (that correspond to classical MTD approaches in medicine) to administrations that also include singular controls (which correspond to time-varying dosing schedules at less than maximum rates) as heterogeneity of the tumor population becomes more prevalent. In this chapter, we begin to analyze mathematical models that also take into account a tumor’s microenvironment.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Jetzt informieren
Vorheriges Kapitel Optimal Control for Problems with a Quadratic Cost Functional on the Therapeutic Agents
Nächstes Kapitel Robust Suboptimal Treatment Protocols for Antiangiogenic Therapy
Literatur
4.
Z. Agur, L. Arakelyan, P. Daugulis and Y. Ginosar, Hopf point analysis for angiogenesis models, Discrete and Continuous Dynamical Systems, Series B, 4(1), (2004), pp. 29–38.MATHMathSciNetCrossRef
28.
T. Boehm, J. Folkman, T. Browder and M.S. O’Reilly, Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Nature, 390, (1997), pp. 404–407.CrossRef
39.
T. Browder, C.E. Butterfield, B.M. Kräling, B. Shi, B. Marshall, M.S. O’Reilly and J. Folkman, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer, Cancer Research, 60, (2000), pp. 1878–1886.
66.
S. Davis and G.D. Yancopoulos, The angiopoietins: Yin and Yang in angiogenesis, Current Topics in Microbiology and Immunology, 237, (1999), pp. 173–185.
69.
T.A. Drixler, I.H. Borel Rinkes, E.D. Ritchie, T.J. van Vroonhoven, M.F. Gebbink and E.E. Voest, Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastasies after partial hepatectomy, Cancer Research, 60, (2000), pp. 1761–1765.
77.
A. Ergun, K. Camphausen and L.M. Wein, Optimal scheduling of radiotherapy and angiogenic inhibitors, Bulletin of Mathematical Biology, 65, (2003), pp. 407–424.CrossRef
85.
J. Folkman, Tumor angiogenesis: therapeutic implications, New England J. of Medicine, 295, (1971), pp. 1182–1196.
86.
J. Folkman, Antiangiogenesis: new concept for therapy of solid tumors, Annals of Surgery, 175, (1972), pp. 409–416.CrossRef
90.
J. Folkman and M. Klagsburn, Angiogenic factors, Science, 235, (1987), pp. 442–447.CrossRef
91.
U. Forys, Y. Keifetz and Y. Kogan, Critical-point analysis for three-variable cancer angiogenesis models, Mathematical Biosciences and Engineering-MBE, 2(3), (2005), pp. 511–525.MATHMathSciNetCrossRef
103.
H. Gardner-Moyer, Sufficient conditions for a strong minimum in singular control problems, SIAM J. Control, 11 (1973), pp. 620–636.MathSciNetCrossRef
116.
P. Hahnfeldt, D. Panigrahy, J. Folkman and L. Hlatky, Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy, Cancer Research, 59, (1999), pp. 4770–4775.
131.
R.K. Jain, Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy, Nature Medicine, 7, (2001), pp. 987–989.CrossRef
132.
R.K. Jain and L.L. Munn, Vascular normalization as a rationale for combining chemotherapy with antiangiogenic agents, Principles of Practical Oncology, 21, (2007), pp. 1–7.
141.
R.S. Kerbel, A cancer therapy resistant to resistance, Nature, 390, (1997), pp. 335–336.CrossRef
160.
O. Kisker, C.M. Becker, D. Prox, M. Fannon, R. d’Amato, E. Flynn, W.E. Fogler, B.K. Sim, E.N. Allred, S.R. Pirie-Shepherd and J. Folkman, Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model, Cancer Research, 61, (2001), pp. 7669–7674.
161.
M. Klagsburn and S. Soker, VEGF/VPF: the angiogenesis factor found?, Current Biology, 3, (1993), pp. 699–702.CrossRef
183.
U. Ledzewicz, J. Munden and H. Schättler, Scheduling of anti-angiogenic inhibitors for Gompertzian and logistic tumor growth models, Discrete and Continuous Dynamical Systems, Series B, 12, (2009), pp. 415–439.
189.
U. Ledzewicz, V. Oussa and H. Schättler, Optimal solutions for a model of tumor anti-angiogenesis with a penalty on the cost of treatment, Applicationes Mathematicae, 36(3), (2009), pp. 295–312.MATHMathSciNetCrossRef
196.
U. Ledzewicz and H. Schättler, A synthesis of optimal controls for a model of tumor growth under angiogenic inhibitors, Proc. of the 44th IEEE Conference on Decision and Control, Sevilla, Spain, December 2005, pp. 934–939.
197.
U. Ledzewicz and H. Schättler, Optimal control for a system modelling tumor anti-angiogenesis, Proc. of the ICGST International Conference on Automatic Control and System Engineering, ACSE-05, Cairo, Egypt, December 2005, pp. 147–152.
200.
U. Ledzewicz and H. Schättler, Application of optimal control to a system describing tumor anti-angiogenesis, Proc. of the 17th International Symposium on Mathematical Theory of Networks and Systems (MTNS), Kyoto, Japan, July 2006, pp. 478-484.
201.
U. Ledzewicz and H. Schättler, Antiangiogenic therapy in cancer treatment as an optimal control problem, SIAM J. on Control and Optimization, 46(3), (2007), pp. 1052–1079.MATHCrossRef
204.
U. Ledzewicz and H. Schättler, Analysis of a mathematical model for tumor anti-angiogenesis, Optimal Control, Applications and Methods, 29(1), (2008), pp. 41–57.MathSciNetCrossRef
205.
U. Ledzewicz and H. Schättler, Effect of the Objective on Optimal Controls for a System Describing Tumor Anti-Angiogenesis, in: New Aspects of Systems, Part II, Proc. of the 12th WSEAS International Conference on Systems, Heraklion, Greece, July 2008, pp. 483-490
206.
U. Ledzewicz and H. Schättler, On the optimality of singular controls for a class of mathematical models for tumor anti-angiogenesis, Discrete and Continuous Dynamical Systems, Series B, 11 (3), (2009), pp. 691–715.MATHMathSciNetCrossRef
251.
A. d’Onofrio, Rapidly acting antitumoral anti-angiogenic therapies, Physical Review E, 76(3), art. no. 031920, (2007).
257.
A. d’Onofrio and A. Gandolfi, Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999), Mathematical Biosciences, 191, (2004), pp. 159–184.
259.
A. d’Onofrio and A. Gandolfi, A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy, Mathematical Medicine and Biology, 26, (2009), pp. 63–95, doi:10.1093/imammb/dqn024.
281.
J. Poleszczuk and U. Forys, Derivation of the Hahnfeldt et al. model (1999) revisited, Proc. of the 16th National Conference on Applications of Mathematics in Biology and Medicine, Krynica, Poland, September 2010, pp. 87–92.
292.
293.
H. Schättler, U. Ledzewicz and B. Cardwell, Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis, Mathematical Biosciences and Engineering- MBE, 8(2), (2011), pp. 355–369.MATHMathSciNetCrossRef
314.
A. Swierniak, Direct and indirect control of cancer populations, Bulletin of the Polish Academy of Sciences, Technical Sciences, 56(4), (2008), pp. 367–378.
316.
A. Swierniak, Comparison of control theoretic properties of models of antiangiogenic therapy, Proc. of the 6th International IASTED Conference on Biomedical Engineering, Acta Press, (2008), pp. 156–160.
319.
A. Swierniak, A. d’Onofrio, A. Gandolfi, Optimal control problems related to tumor angiogenesis, Proc. IEEE-IECON’2006, pp. 667–681.
320.
A. Swierniak, G. Gala, A. Gandolfi and A. d’Onofrio, Optimization of angiogenic therapy as optimal control problem, Proc. of the 4th IASTED Conference on Biomechanics, Acta Press, (M. Doblare, Ed.), (2006), pp. 56–60.
Metadaten
Titel
Optimal Control of Mathematical Models for Antiangiogenic Treatments
verfasst von
Heinz Schättler
Urszula Ledzewicz
Copyright-Jahr
2015
Verlag
Springer New York
Buch
Optimal Control for Mathematical Models of Cancer Therapies

Print ISBN: 978-1-4939-2971-9

Electronic ISBN: 978-1-4939-2972-6

Copyright-Jahr: 2015

DOI
https://doi.org/10.1007/978-1-4939-2972-6_5

Premium Partner

    Bildnachweise